Leerink Partnrs Forecasts Vaxcyte FY2029 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX) – Investment analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of Vaxcyte in a note issued to investors on Sunday, January 12th. Leerink Partnrs analyst D. Risinger anticipates that the company will earn $2.42 per share for the year. The consensus estimate for Vaxcyte’s current full-year earnings is ($4.14) per share.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter last year, the company earned ($0.91) EPS.

Several other research analysts also recently issued reports on PCVX. The Goldman Sachs Group assumed coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte presently has a consensus rating of “Buy” and a consensus target price of $145.71.

Vaxcyte Trading Up 0.1 %

Shares of NASDAQ PCVX opened at $81.17 on Tuesday. The stock has a 50-day moving average price of $89.69 and a two-hundred day moving average price of $93.54. Vaxcyte has a 12 month low of $58.10 and a 12 month high of $121.06. The company has a market cap of $10.12 billion, a price-to-earnings ratio of -17.65 and a beta of 0.98.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Riverview Trust Co bought a new stake in shares of Vaxcyte during the 3rd quarter worth $27,000. Blue Trust Inc. lifted its stake in Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after purchasing an additional 93 shares during the last quarter. Quest Partners LLC purchased a new position in shares of Vaxcyte in the 2nd quarter worth about $70,000. Meeder Asset Management Inc. increased its position in shares of Vaxcyte by 1,007.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after purchasing an additional 635 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. purchased a new position in shares of Vaxcyte during the 3rd quarter valued at about $92,000. Institutional investors own 96.78% of the company’s stock.

Insider Activity

In other Vaxcyte news, CFO Andrew Guggenhime sold 42,000 shares of the firm’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00. Following the completion of the sale, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at $10,429,294.37. This trade represents a 31.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $106.82, for a total value of $1,602,300.00. Following the completion of the sale, the chief executive officer now directly owns 435,219 shares of the company’s stock, valued at approximately $46,490,093.58. This trade represents a 3.33 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 113,732 shares of company stock valued at $11,730,787 over the last three months. Corporate insiders own 3.10% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.